搜索筛选:
搜索耗时0.0827秒,为你在为你在102,285,761篇论文里面共找到 3 篇相符的论文内容
发布年度:
,Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against hu
[期刊论文] 作者：Qin XIE,Hui CHEN,Jing AI,Ying-lei GAO,Mei-yu GENG,Jian DING,Yi CHEN,
来源：中国药理学报（英文版） 年份：2017
Thyroid cancer is the most common type of endocrine neoplasia.Despite recent breakthroughs in treatment of the disease,the treatment of advanced,progressive thy...
,Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase
[期刊论文] 作者：Xue-mei LIAO,Yi CHEN,Yan-yan SHEN,Xin-ying YANG,Yi SU,Yi-ming SUN,Ying-lei GAO,Jian DING,Ao ZHANG,Jin-xue,
来源：中国药理学报（英文版） 年份：2017
Over half of patients with BRCA1-deficient cancers do not respond to treatment with poly(ADP-ribose) polymerase (PARP) inhibitors.In this study,we report that a...
SAF-189s,a potent new-generation ROS1 inhibitor,is active against crizotinib-resistant ROS1 mutant-d
[期刊论文] 作者：Zong-jun Xia,Yin-chun Ji,De-qiao Sun,Xia Peng,Ying-lei Gao,Yan-fen Fang,Xing-dong Zhao,Wei-bo Wang,Jian,
来源：中国药理学报（英文版） 年份：2021
The ROS1 fusion kinase is an attractive antitumor target.Though with significant clinical efficacy,the well-known first-generation ROS1 inhibitor(ROS1 i)crizotinib inevitably developed acquired resistance due to secondary point mutations in......
相关搜索：
